196 related articles for article (PubMed ID: 12803927)
1. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
Butters TD; Mellor HR; Narita K; Dwek RA; Platt FM
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):927-45. PubMed ID: 12803927
[TBL] [Abstract][Full Text] [Related]
2. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
Butters TD; Dwek RA; Platt FM
Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
[TBL] [Abstract][Full Text] [Related]
3. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
Butters TD; Dwek RA; Platt FM
Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic applications of imino sugars in lysosomal storage disorders.
Butters TD; Dwek RA; Platt FM
Curr Top Med Chem; 2003; 3(5):561-74. PubMed ID: 12570866
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
[TBL] [Abstract][Full Text] [Related]
6. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.
Aerts JM; Hollak C; Boot R; Groener A
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):905-14. PubMed ID: 12803924
[TBL] [Abstract][Full Text] [Related]
7. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann RH
Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives for glycolipid research in medicine.
Cox TM
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):967-73. PubMed ID: 12803931
[TBL] [Abstract][Full Text] [Related]
9. Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain.
Lachmann RH
Expert Rev Endocrinol Metab; 2009 May; 4(3):217-224. PubMed ID: 30743792
[TBL] [Abstract][Full Text] [Related]
10. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
11. Substrate reduction therapy for glycosphingolipid storage disorders.
Lachmann RH; Platt FM
Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
[TBL] [Abstract][Full Text] [Related]
12. Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
Platt FM; Butters TD
Expert Rev Mol Med; 2000 Feb; 2(1):1-17. PubMed ID: 14585134
[TBL] [Abstract][Full Text] [Related]
13. Substrate reduction therapy in mouse models of the glycosphingolipidoses.
Platt FM; Jeyakumar M; Andersson U; Heare T; Dwek RA; Butters TD
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):947-54. PubMed ID: 12803928
[TBL] [Abstract][Full Text] [Related]
14. Substrate reduction therapy.
Platt FM; Jeyakumar M
Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
[TBL] [Abstract][Full Text] [Related]
15. A historical perspective of the glycosphingolipids and sphingolipidoses.
Watts RW
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):975-83. PubMed ID: 12803932
[TBL] [Abstract][Full Text] [Related]
16. The pathogenesis of glycosphingolipid storage disorders.
Ginzburg L; Kacher Y; Futerman AH
Semin Cell Dev Biol; 2004 Aug; 15(4):417-31. PubMed ID: 15207832
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biochemical pathophysiology of ataxia in the sphingolipidoses.
Philippart M
Adv Neurol; 1978; 21():131-49. PubMed ID: 104554
[TBL] [Abstract][Full Text] [Related]
18. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
Gatt S; Dagan A
Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.
Platt FM; Butters TD
Biochem Pharmacol; 1998 Aug; 56(4):421-30. PubMed ID: 9763217
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the biochemistry and genetics of sphingolipidoses.
Ozkara HA
Brain Dev; 2004 Dec; 26(8):497-505. PubMed ID: 15533650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
